Herpes zoster in post-covid era: a case study
https://doi.org/10.22625/2072-6732-2025-17-3-169-174
Abstract
Herpes Zoster is a manifest disease caused by the reactivation of the type 3 herpes virus Varicella Zoster as a result of immunological or hormonal stress. Since 2021, the Russian Federation has a stable tendency to increase of Varicella incidence due to the beginning of a new long-term epidemic cycle. Since Herpes Zoster is secondary to Varicella, the recurrent form of infection has been subject to statistical monitoring in the Russian Federation since 2019. The analysis of the data obtained shows that Herpes Zoster is present in all age groups, including infants, and its incidence increases with age. The increase of Herpes Zoster incidence is caused not merely by the rise of Varicella, but also with the recent Covid-19 pandemia, since adults who have experienced a new coronaviral infection are more likely to catch Herpes Zoster. The article provides a clinical case of Herpes Zoster that developed in a 5-year-old child as a result of maternal Varicella at 30 weeks pregnant.
About the Authors
Yu. V. Vyaltseva
Medical Institute named after S.I. Georgievsky of Crimean Federal University named after V.I. Vernadsky
Russian Federation
Competing Interests:
Russian Federation
Simferopol
Competing Interests:
None
N. V. Rymarenko
Medical Institute named after S.I. Georgievsky of Crimean Federal University named after V.I. Vernadsky
Russian Federation
Competing Interests:
Russian Federation
Simferopol
Competing Interests:
None
E. S. Chernyaeva
Medical Institute named after S.I. Georgievsky of Crimean Federal University named after V.I. Vernadsky
Russian Federation
Competing Interests:
Russian Federation
Simferopol
Competing Interests:
None
References
1. Harbecke R, Cohen JI, Oxman MN. Herpes zoster vaccines. J Infect Dis. 2021;224(Suppl._4):S429–S442. doi:10.1093/infdis/jiab387.
2. Vrozhdennaya vetryanaya ospa: klinicheskij sluchaj u rebenka v vozraste shesti dnej / V. N. Timchenko, T. A. Kaplina, S. L. Bannova [i dr.] // Pediatr. – 2018. – T. 9, № 1. – S. 100–105. (In Russ.) doi: 10.17816/PED91100-105
3. Patil A, Goldust M, Wollina U. Herpes zoster: A Review of Clinical Manifestations and Management. Viruses. 2022 Jan 19;14(2):192. doi: 10.3390/v14020192. PMID: 35215786; PMCID: PMC8876683
4. Hakami MA, Khan FR, Abdulaziz O, Alshaghdali K, Hazazi A, Aleissi AF, Abalkhail A, Alotaibi BS, Alhazmi AYM, Kukreti N, Binshaya AS. Varicella-zoster virus-related neurological complications: From infection to immunomodulatory therapies. Rev Med Virol. 2024 Jul;34(4):e2554. doi: 10.1002/rmv.2554. PMID: 38862398.
5. Sluchaj opoyasyvayushchego gerpesa u rebenka grudnogo vozrasta / E. N. Sergienko, N. A. Rybak, O. N. Romanova [i dr.] // Klinicheskaya infektologiya i parazitologiya. – 2023. – T. 12, № 3. – S. 281– 286. (In Russ.)
6. Tarasenko G. N. Opoyasyvayushchij lishaj: problema dermatologa ili nevropatologa? / G. N. Tarasenko, Yu. G. Tarasenko, V. V. Shabel’skaya // Gospital’naya medicina: nauka i praktika. – 2022. – T.5, №5. – S.46–49. (In Russ.) doi:10.34852/GM3CVKG.2022.30.28.008
7. Gosudarstvennyj doklad «O sostoyanii sanitarno – epidemiologicheskogo blagopoluchiya naseleniya v Rossijskoj Federacii v 2023 godu». – Rezhim dostupa: https://www.rospotrebnadzor.ru/upload/iblock/fbc/sd3prfszlc9c2r4xbms-b7o3us38nrvpk/Gosudarstvennyy-doklad-_O-sostoyanii-sanitarno_epidemiologicheskogo-blagopoluchiya-naseleniya-v-Rossiyskoy-Federatsii-v-2023-godu_..pdf
8. Chen YC, Ho CH, Liu TH, et al. Long-term risk of herpes zoster following COVID-19: a retrospective cohort study of 2 442 686 patients. J Med Virol. 2023;95(4):e28745. https://doi.org/10.1002/jmv.28745.].
9. Osobennosti kliniki opoyasyvayushchego gerpesa u grudnyh detej / A.S. Shishov, A. K. Shakaryan, I. H. Belyaletdinova, I.V. Mitrofanova // Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. – 2019. – T.119, №7, vyp. 2. – S. 67–73. (In Russ.)
10. Srikanth P, Arumugam I, Jeganathan SN, Ramesh R, Ranganathan LN, Vijayaraghavan S, Expanded spectrum of varicella disease and the need for vaccination in India. Human Vaccines and Immunotherapeautics. 2024 Dec 31;20(1): 2328955
11. Vaccines and immunization About the Varicella Vaccines. – 2021. August 6. https://www.cdc.gov/vaccines/vpd/varicella/hcp/about-vaccine.html
12. Blumental S, Lepage P. Management of varicella in neonates and infants. BMJ Paediatr. Open. 2019;3:e000433. doi: 10.1136/bmjpo-2019-000433.
13. Camila K Janniger, MD. Herpes Zoster Treatment & Management: Approach Considerations, Topical Treatments, Pharmacologic Therapy for Herpes Zoster, Medscape. 2021, July 21
14. Patokar Abhishek S, Holani Aditya R, Khatu Swapna, Chaudhari Nitin, Palaskar Nachiket F. et al. Varicella Syndrome – A Rare Case Report and Literature Review. Clinical Dermatology Review. 2022; 6(1):57. doi: 10.4103/CDR.CDR_118_20
15. Vetryanaya ospa u beremennyh: sovremennye podhody k diagnostike, profilaktike i lecheniyu: metodicheskiye rekomendatsii / sostavireli: I. V. Koltsova, L. B. Kistenyova, S. V. Smetanina [i dr.]. – Moskva.: GBUZ «IKB № 1 DZM», 2025. – 40 s. (In Russ.)
16. Bhavsar SM, Mangat C. Congenital Varicella Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. 2023 Mar 6.
Review
For citations:
Vyaltseva Yu.V., Rymarenko N.V., Chernyaeva E.S. Herpes zoster in post-covid era: a case study. Journal Infectology. 2025;17(3):169-174. (In Russ.) https://doi.org/10.22625/2072-6732-2025-17-3-169-174
Views:
5
.png)
.png)
Email this article 